Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.05, read 2026-10-24
Ethical does not pass the values gate
Price7.67 USD
Ethical score70.0/100
Our investment reviews on this name
2026-09-11Read Accumulation6.31+21.6% to today ✓Distribution gives way to Accumulation after a 6% rise in 4 weeks
2026-08-11Read Distribution5.94+29.1% to today Markdown gives way to Distribution after a 68% slide in 6 weeks
2026-07-02Read Markdown18.83-59.3% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Regencell Bioscience Holdings Ltd holds its Accumulation at $7.67. Elevated stress, defensive posture warranted, held for 48 days.
As held on the ledger · 2026-10-23
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 48 days
Price at the screen
$7.67
Valuation
N/A trailing · N/A forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.49
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.02%
Below 33%
Interest-bearing debt is just 1.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
59.25%
Below 33%
Interest-bearing cash and securities are 59.3% of assets, above the one-third limit.
Fail
Receivables
36.90%
Below 49%
Money owed to the company is 36.9% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Regencell Bioscience's business is fine, but its cash and interest-bearing securities are about 59% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RGC's ethical verdict changes
Today RGC does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The risks · The things to watch: it already moves more than the market on an average day; its business and earnings are exposed to Hong Kong and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RGC trades on NASDAQ (the company is based in Hong Kong). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-25Accumulation$8.11+0.0%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%.
2026-10-18Accumulation$8.11+40.1%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 40.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 0% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%.
2026-10-02Accumulation$5.79-8.2%Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 8.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 0% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%.
2026-09-11Accumulation · changed$6.31+6.2%Entry 5
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 0% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 68.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 0% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%.
2026-07-18Markdown$18.83+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 0% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%.
2026-07-03Markdown$18.83+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$18.83Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
